DK1682185T3 - Kompositioner og fremgangsmåder til behandling af et posterior segment af et öje - Google Patents

Kompositioner og fremgangsmåder til behandling af et posterior segment af et öje

Info

Publication number: DK1682185T3
Authority: DK; Denmark
Prior art keywords: component; eye; posterior segment; corticosteroid; composition
Prior art date: 2003-11-12

Application number

DK04810635T

Other languages

Danish (da)

English (en)

Inventor

Robert T Lyons

James N Chang

John T Trogden

Scott M Whitcup

Original Assignee

Allergan Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-12

Filing date

2004-11-08

Publication date

2009-04-20

2004-11-08 Application filed by Allergan Inc filed Critical Allergan Inc

2009-04-20 Application granted granted Critical

2009-04-20 Publication of DK1682185T3 publication Critical patent/DK1682185T3/da

Links

239000000203 mixture Substances 0.000 title abstract 5
239000003246 corticosteroid Substances 0.000 abstract 3
229920002125 Sokalan® Polymers 0.000 abstract 2
230000001939 inductive effect Effects 0.000 abstract 2
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 1
229920001353 Dextrin Polymers 0.000 abstract 1
239000004375 Dextrin Substances 0.000 abstract 1
108010010803 Gelatin Proteins 0.000 abstract 1
229920000148 Polycarbophil calcium Polymers 0.000 abstract 1
239000004372 Polyvinyl alcohol Substances 0.000 abstract 1
239000008365 aqueous carrier Substances 0.000 abstract 1
235000019425 dextrin Nutrition 0.000 abstract 1
229920000159 gelatin Polymers 0.000 abstract 1
239000008273 gelatin Substances 0.000 abstract 1
235000019322 gelatine Nutrition 0.000 abstract 1
235000011852 gelatine desserts Nutrition 0.000 abstract 1
150000004676 glycans Chemical class 0.000 abstract 1
229920002674 hyaluronan Polymers 0.000 abstract 1
229960003160 hyaluronic acid Drugs 0.000 abstract 1
238000002347 injection Methods 0.000 abstract 1
239000007924 injection Substances 0.000 abstract 1
239000002184 metal Substances 0.000 abstract 1
239000002245 particle Substances 0.000 abstract 1
229920002401 polyacrylamide Polymers 0.000 abstract 1
239000004584 polyacrylic acid Substances 0.000 abstract 1
229950005134 polycarbophil Drugs 0.000 abstract 1
229920001282 polysaccharide Polymers 0.000 abstract 1
239000005017 polysaccharide Substances 0.000 abstract 1
229920002689 polyvinyl acetate Polymers 0.000 abstract 1
239000011118 polyvinyl acetate Substances 0.000 abstract 1
229920002451 polyvinyl alcohol Polymers 0.000 abstract 1
239000003755 preservative agent Substances 0.000 abstract 1
230000002335 preservative effect Effects 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Inorganic Chemistry (AREA)
Ophthalmology & Optometry (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pulmonology (AREA)
AIDS & HIV (AREA)
Heart & Thoracic Surgery (AREA)
Molecular Biology (AREA)
Cardiology (AREA)
Surgery (AREA)
Dispersion Chemistry (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Steroid Compounds (AREA)

DK04810635T 2003-11-12 2004-11-08 Kompositioner og fremgangsmåder til behandling af et posterior segment af et öje DK1682185T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US51923703P	2003-11-12	2003-11-12
US53006203P	2003-12-16	2003-12-16
US10/966,764 US20050101582A1 (en)	2003-11-12	2004-10-14	Compositions and methods for treating a posterior segment of an eye
PCT/US2004/037436 WO2005046641A2 (fr)	2003-11-12	2004-11-08	Compositions et procedes pour traiter un segment posterieur de l'oeil

Publications (1)

Publication Number	Publication Date
DK1682185T3 true DK1682185T3 (da)	2009-04-20

Family

ID=34557415

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK04810635T DK1682185T3 (da)	2003-11-12	2004-11-08	Kompositioner og fremgangsmåder til behandling af et posterior segment af et öje
DK08016371.0T DK1997497T3 (da)	2003-11-12	2004-11-08	Sammensætninger og fremgangsmåder til behandling af et posteriort segment af et øje

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK08016371.0T DK1997497T3 (da)	2003-11-12	2004-11-08	Sammensætninger og fremgangsmåder til behandling af et posteriort segment af et øje

Country Status (19)

Country	Link
US (3)	US20050101582A1 (fr)
EP (2)	EP1682185B1 (fr)
JP (2)	JP5437563B2 (fr)
KR (1)	KR20060113709A (fr)
CN (1)	CN105748407A (fr)
AT (2)	ATE424220T1 (fr)
AU (2)	AU2004289300B2 (fr)
BR (1)	BRPI0416506A (fr)
CA (1)	CA2545878C (fr)
CY (2)	CY1110469T1 (fr)
DE (2)	DE602004019801D1 (fr)
DK (2)	DK1682185T3 (fr)
ES (2)	ES2321305T3 (fr)
NZ (1)	NZ546699A (fr)
PL (2)	PL213709B1 (fr)
PT (2)	PT1682185E (fr)
SI (2)	SI1997497T1 (fr)
TW (1)	TWI362264B (fr)
WO (1)	WO2005046641A2 (fr)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5869079A (en) *	1995-06-02	1999-02-09	Oculex Pharmaceuticals, Inc.	Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US20060280774A1 (en) *	1995-06-02	2006-12-14	Allergan, Inc.	Compositions and methods for treating glaucoma
US6726918B1 (en)	2000-07-05	2004-04-27	Oculex Pharmaceuticals, Inc.	Methods for treating inflammation-mediated conditions of the eye
AU2002236495B2 (en) *	2000-11-29	2006-05-11	Allergan, Inc.	Intraocular implants for preventing transplant rejection in the eye
US20050048099A1 (en)	2003-01-09	2005-03-03	Allergan, Inc.	Ocular implant made by a double extrusion process
FR2861734B1 (fr)	2003-04-10	2006-04-14	Corneal Ind	Reticulation de polysaccharides de faible et forte masse moleculaire; preparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus
US20090148527A1 (en) *	2007-12-07	2009-06-11	Robinson Michael R	Intraocular formulation
US20050250737A1 (en) *	2003-11-12	2005-11-10	Allergan, Inc.	Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20060141049A1 (en) *	2003-11-12	2006-06-29	Allergan, Inc.	Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20070224278A1 (en) *	2003-11-12	2007-09-27	Lyons Robert T	Low immunogenicity corticosteroid compositions
US20050101582A1 (en) *	2003-11-12	2005-05-12	Allergan, Inc.	Compositions and methods for treating a posterior segment of an eye
CN100548271C (zh)	2004-01-20	2009-10-14	阿勒根公司	用于眼部的局部治疗、并优选包括有曲安奈德及透明质酸的组合物
US8147865B2 (en)	2004-04-30	2012-04-03	Allergan, Inc.	Steroid-containing sustained release intraocular implants and related methods
US8119154B2 (en)	2004-04-30	2012-02-21	Allergan, Inc.	Sustained release intraocular implants and related methods
US20050244469A1 (en)	2004-04-30	2005-11-03	Allergan, Inc.	Extended therapeutic effect ocular implant treatments
CA2573668A1 (fr) *	2004-07-12	2006-02-16	Allergan, Inc.	Compositions ophtalmiques et procedes de traitement de conditions ophtalmiques
US20060073184A1 (en) *	2004-09-29	2006-04-06	Bausch & Lomb Inc.	Viscoelastic composition, methods of use and packaging device with anti-oxidant
US20080008762A1 (en) *	2004-11-17	2008-01-10	Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services	Steroid Formulation And Methods Of Treatment Using Same
AT501376B1 (de) *	2005-01-17	2010-11-15	Pregenzer Bruno	Glucokortikoid-hältiges arzneimittel
SI1845780T1 (sl) *	2005-01-20	2012-01-31	Inst Molecular Medicine Inc	Uporaba derivatov metilfenidata
AU2006206410B2 (en)	2005-01-20	2012-08-30	Ampio Pharmaceuticals, Inc.	Methylphenidate derivatives and uses of them
DE202006021081U1 (de)	2005-07-12	2012-05-08	Dmi Biosciences, Inc.	Produkte zur Behandlung von Krankheiten
US20090082321A1 (en) *	2007-09-21	2009-03-26	Allergan, Inc.	Steroid containing drug delivery systems
WO2007047607A2 (fr) *	2005-10-18	2007-04-26	Allergan, Inc.	Therapie oculaire utilisant des derives de glucocorticoides traversant selectivement les tissus du segment posterieur
US20070178138A1 (en) *	2006-02-01	2007-08-02	Allergan, Inc.	Biodegradable non-opthalmic implants and related methods
US20070202186A1 (en)	2006-02-22	2007-08-30	Iscience Interventional Corporation	Apparatus and formulations for suprachoroidal drug delivery
US8197435B2 (en) *	2006-05-02	2012-06-12	Emory University	Methods and devices for drug delivery to ocular tissue using microneedle
US20070260203A1 (en) *	2006-05-04	2007-11-08	Allergan, Inc.	Vasoactive agent intraocular implant
US20070275030A1 (en) *	2006-05-25	2007-11-29	The General Hospital Corporation Dba Massachusetts General Hospital	Anti-cross-linking agents and methods for inhibiting cross-linking of injectable hydrogel formulations
US8802128B2 (en)	2006-06-23	2014-08-12	Allergan, Inc.	Steroid-containing sustained release intraocular implants and related methods
US8969415B2 (en) *	2006-12-01	2015-03-03	Allergan, Inc.	Intraocular drug delivery systems
US11078262B2 (en) *	2007-04-30	2021-08-03	Allergan, Inc.	High viscosity macromolecular compositions for treating ocular conditions
EP2152743A2 (fr) *	2007-05-23	2010-02-17	Allergan, Inc.	Collagène réticulé et utilisations de ce dernier
US8318695B2 (en) *	2007-07-30	2012-11-27	Allergan, Inc.	Tunably crosslinked polysaccharide compositions
US8697044B2 (en)	2007-10-09	2014-04-15	Allergan, Inc.	Crossed-linked hyaluronic acid and collagen and uses thereof
EP3498299A1 (fr)	2007-11-16	2019-06-19	Aclaris Therapeutics, Inc.	Compositions et procedes de traitement du purpura
US20090143348A1 (en) *	2007-11-30	2009-06-04	Ahmet Tezel	Polysaccharide gel compositions and methods for sustained delivery of drugs
US8394784B2 (en) *	2007-11-30	2013-03-12	Allergan, Inc.	Polysaccharide gel formulation having multi-stage bioactive agent delivery
US8394782B2 (en) *	2007-11-30	2013-03-12	Allergan, Inc.	Polysaccharide gel formulation having increased longevity
US9161970B2 (en) *	2007-12-12	2015-10-20	Allergan, Inc.	Dermal filler
US9044477B2 (en)	2007-12-12	2015-06-02	Allergan, Inc.	Botulinum toxin formulation
PT2262506E (pt)	2008-03-11	2014-06-24	Alcon Res Ltd	Suspensões de acetonido de triamcinolona de baixa viscosidade altamente floculadas para injeção intravítrea
WO2009146320A1 (fr)	2008-05-27	2009-12-03	Dmi Life Sciences, Inc.	Procédés et composés thérapeutiques
US8821870B2 (en)	2008-07-18	2014-09-02	Allergan, Inc.	Method for treating atrophic age related macular degeneration
US8450475B2 (en) *	2008-08-04	2013-05-28	Allergan, Inc.	Hyaluronic acid-based gels including lidocaine
JP5722217B2 (ja)	2008-09-02	2015-05-20	アラーガン・ホールディングス・フランス・ソシエテ・パール・アクシオン・サンプリフィエＡｌｌｅｒｇａｎＨｏｌｄｉｎｇｓＦｒａｎｃｅＳ．Ａ．Ｓ．	ヒアルロン酸および／またはその誘導体の糸、その作製方法、ならびにその使用
US20100098772A1 (en) *	2008-10-21	2010-04-22	Allergan, Inc.	Drug delivery systems and methods for treating neovascularization
US20100104654A1 (en)	2008-10-27	2010-04-29	Allergan, Inc.	Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
GB0904423D0 (en) *	2009-03-14	2009-04-29	Univ Strathclyde	Improving the solubility of chemicals
US20100278897A1 (en) *	2009-05-01	2010-11-04	Allergan, Inc.	Intraocular bioactive agent delivery system with molecular partitioning system
DK2326332T3 (da)	2009-06-22	2013-03-04	Dmi Acquistion Corp	Fremgangsmåde til behandling af sygdomme
EP2512389B1 (fr)	2009-12-16	2015-09-02	Allergan, Inc.	Dispositifs intracamérulaires pour administration prolongée
US20110171286A1 (en) *	2010-01-13	2011-07-14	Allergan, Inc.	Hyaluronic acid compositions for dermatological use
US20110172180A1 (en)	2010-01-13	2011-07-14	Allergan Industrie. Sas	Heat stable hyaluronic acid compositions for dermatological use
US20110171311A1 (en) *	2010-01-13	2011-07-14	Allergan Industrie, Sas	Stable hydrogel compositions including additives
US9114188B2 (en)	2010-01-13	2015-08-25	Allergan, Industrie, S.A.S.	Stable hydrogel compositions including additives
US8647659B2 (en) *	2010-01-22	2014-02-11	Allergan, Inc.	Intracameral sustained release therapeutic agent implants
CA2792729C (fr) *	2010-03-12	2016-06-28	Allergan Industrie, Sas	Composition fluide pour l'amelioration d'etats cutanes
HUE030138T2 (en)	2010-03-22	2017-04-28	Allergan Inc	Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
CN102883709A (zh) *	2010-04-07	2013-01-16	阿勒根公司	用于眼用制剂的防腐组合物联合
US8883139B2 (en)	2010-08-19	2014-11-11	Allergan Inc.	Compositions and soft tissue replacement methods
US8889123B2 (en)	2010-08-19	2014-11-18	Allergan, Inc.	Compositions and soft tissue replacement methods
US9005605B2 (en)	2010-08-19	2015-04-14	Allergan, Inc.	Compositions and soft tissue replacement methods
US8697057B2 (en)	2010-08-19	2014-04-15	Allergan, Inc.	Compositions and soft tissue replacement methods
US8507496B2 (en)	2010-09-07	2013-08-13	Dmi Acquisition Corp.	Treatment of diseases
EP2627292B1 (fr)	2010-10-15	2018-10-10	Clearside Biomedical, Inc.	Dispositif pour accès oculaire
US11957753B2 (en)	2010-11-22	2024-04-16	Bausch Health Ireland Limited	Pharmaceutical formulations containing corticosteroids for topical administration
US8809307B2 (en) *	2010-11-22	2014-08-19	Dow Pharmaceutical Sciences, Inc.	Pharmaceutical formulations containing corticosteroids for topical administration
US9408797B2 (en)	2011-06-03	2016-08-09	Allergan, Inc.	Dermal filler compositions for fine line treatment
AU2012262047A1 (en)	2011-06-03	2014-01-16	Allergan, Inc.	Dermal filler compositions including antioxidants
US9393263B2 (en)	2011-06-03	2016-07-19	Allergan, Inc.	Dermal filler compositions including antioxidants
US20130096081A1 (en)	2011-06-03	2013-04-18	Allergan, Inc.	Dermal filler compositions
US9662422B2 (en)	2011-09-06	2017-05-30	Allergan, Inc.	Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
US20130244943A1 (en)	2011-09-06	2013-09-19	Allergan, Inc.	Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
US9241829B2 (en)	2011-12-20	2016-01-26	Abbott Medical Optics Inc.	Implantable intraocular drug delivery apparatus, system and method
WO2014063155A1 (fr)	2012-10-21	2014-04-24	University Of Rochester	Thy1 (cd90) en tant que nouvelle thérapie pour réguler l'accumulation de tissu adipeux
KR102467714B1 (ko)	2012-11-08	2022-11-16	클리어사이드 바이오메디컬, 인코포레이드	인간 대상체에서 안구 질병을 치료하기 위한 방법 및 장치
CN104968350A (zh)	2012-12-19	2015-10-07	安皮奥制药股份有限公司	疾病的治疗方法
US20150352142A1 (en) *	2013-01-11	2015-12-10	Carbylan Therapeutics, Inc.	Stabilized compositions comprising hyaluronic acid
NZ709620A (en) *	2013-01-23	2020-07-31	Semnur Pharmaceuticals Inc	Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid
EP2986635B1 (fr)	2013-04-18	2018-10-03	Fondazione Telethon	Administration efficace de grands gènes par des vecteurs aav doubles
AU2014259694B2 (en)	2013-05-03	2018-11-08	Clearside Biomedical, Inc.	Apparatus and methods for ocular injection
US10188550B2 (en)	2013-06-03	2019-01-29	Clearside Biomedical, Inc.	Apparatus and methods for drug delivery using multiple reservoirs
EP3119392A4 (fr)	2014-03-17	2017-10-11	Encompass Development Inc.	Formulations oculaires
CN107072765A (zh) *	2014-06-17	2017-08-18	科尼尔赛德生物医学公司	用于治疗后眼病症的方法和装置
WO2015196085A2 (fr)	2014-06-20	2015-12-23	Clearside Biomedical, Inc.	Canule à diamètre variable et procédés de commande de profondeur d'insertion pour administration de médicaments
WO2016051219A1 (fr)	2014-09-30	2016-04-07	Allergan Industrie, Sas	Compositions d'hydrogel stables pourvues d'additifs
WO2016128783A1 (fr)	2015-02-09	2016-08-18	Allergan Industrie Sas	Compositions et méthodes pour améliorer l'apparence de la peau
EP3653232A1 (fr)	2015-02-13	2020-05-20	Allergan Industrie, SAS	Implants pour sculpter, augmenter ou corriger des caractéristiques faciales telles que le menton
WO2017139375A1 (fr)	2016-02-10	2017-08-17	Clearside Biomedical, Inc.	Kit d'injection oculaire, conditionnement et procédés d'utilisation
WO2017192565A1 (fr)	2016-05-02	2017-11-09	Clearside Biomedical, Inc.	Systèmes et méthodes pour l'administration de médicaments par voie ophtalmique
US10973681B2 (en)	2016-08-12	2021-04-13	Clearside Biomedical, Inc.	Devices and methods for adjusting the insertion depth of a needle for medicament delivery
US11273072B2 (en)	2017-01-13	2022-03-15	Gyroscope Therapeutics Limited	Suprachoroidal injection device
US12090294B2 (en)	2017-05-02	2024-09-17	Georgia Tech Research Corporation	Targeted drug delivery methods using a microneedle
AU2019207515B2 (en)	2018-01-10	2024-11-14	Eye Co Pty Ltd	Medical device and pharmaceutical composition for treatment of an eye disease or condition
IT201800007683A1 (it)	2018-07-31	2020-01-31	Altergon Sa	Composizioni cooperative sinergiche utili per aumento del tessuto molle, rilascio di farmaco e campi correlati
IT201800010415A1 (it) *	2018-11-19	2020-05-19	Innate S R L	Composizione iniettabile comprendente acido ialuronico e trealosio e uso della detta composizione.
WO2020171889A1 (fr)	2019-02-19	2020-08-27	University Of Rochester	Blocage de l'accumulation des lipides ou de l'inflammation dans la maladie oculaire thyroïdienne
US20220387554A1 (en) *	2021-06-04	2022-12-08	Mark H. Nelson	Treatments for exudative maculopathies
CN118021719A (zh) *	2022-11-11	2024-05-14	北京华视诺维医疗科技有限公司	一种曲安奈德组合物及其制备方法

Family Cites Families (208)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT252264B (de) *	1965-03-17	1967-02-10	Etapharm Chem Pharm Lab Ges M	Verfahren zur Herstellung eines reinen hochviskosen Hyaluronsäurepräparates
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US3916899A (en)	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
SE390255B (sv) *	1974-02-18	1976-12-13	N G Y Torphammar	Upprullningsanordning foretredesvis for ett sekerhetsbelte i ett fordon
GB1478759A (en) *	1974-11-18	1977-07-06	Alza Corp	Process for forming outlet passageways in pills using a laser
US3966749A (en) *	1975-02-10	1976-06-29	Interx Research Corporation	Novel synthesis of optically active m-acyloxy-α-[(methylamino)methyl]benzyl alcohols, the pharmaceutically acceptable acid addition salts thereof and intermediate useful in the preparation thereof
US4014335A (en) *	1975-04-21	1977-03-29	Alza Corporation	Ocular drug delivery device
US4144317A (en) *	1975-05-30	1979-03-13	Alza Corporation	Device consisting of copolymer having acetoxy groups for delivering drugs
US4052505A (en)	1975-05-30	1977-10-04	Alza Corporation	Ocular therapeutic system manufactured from copolymer
US4057619A (en)	1975-06-30	1977-11-08	Alza Corporation	Ocular therapeutic system with selected membranes for administering ophthalmic drug
US4063064A (en)	1976-02-23	1977-12-13	Coherent Radiation	Apparatus for tracking moving workpiece by a laser beam
US4186184A (en) *	1977-12-27	1980-01-29	Alza Corporation	Selective administration of drug with ocular therapeutic system
US4190642A (en) *	1978-04-17	1980-02-26	Alza Corporation	Ocular therapeutic system for dispensing a medication formulation
US4200098A (en) *	1978-10-23	1980-04-29	Alza Corporation	Osmotic system with distribution zone for dispensing beneficial agent
US4285987A (en)	1978-10-23	1981-08-25	Alza Corporation	Process for manufacturing device with dispersion zone
US4303637A (en)	1980-04-04	1981-12-01	Alza Corporation	Medication indicated for ocular hypertension
US4281654A (en)	1980-04-07	1981-08-04	Alza Corporation	Drug delivery system for controlled ocular therapy
US4396625A (en)	1980-05-13	1983-08-02	Sumitomo Chemical Company, Limited	Treatment of glaucoma or ocular hypertension and ophthalmic composition
US4425346A (en) *	1980-08-01	1984-01-10	Smith And Nephew Associated Companies Limited	Pharmaceutical compositions
US4304765A (en)	1980-10-14	1981-12-08	Alza Corporation	Ocular insert housing steroid in two different therapeutic forms
US4327725A (en) *	1980-11-25	1982-05-04	Alza Corporation	Osmotic device with hydrogel driving member
US4383992A (en) *	1982-02-08	1983-05-17	Lipari John M	Water-soluble steroid compounds
JPS58126435U (ja)	1982-02-19	1983-08-27	オリンパス光学工業株式会社	Ｔｔｌオ−トストロボ用絞り制御回路
US4599353A (en) *	1982-05-03	1986-07-08	The Trustees Of Columbia University In The City Of New York	Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
DE3220156C2 (de) *	1982-05-28	1990-01-25	Heida Houston Tex. Thurlow	Mit Metallgriffen, insbesondere Edelstahlgriffen, versehenes Koch- und Bratgeschirr mit Deckel
US4649151A (en) *	1982-09-27	1987-03-10	Health Research, Inc.	Drugs comprising porphyrins
IT1229075B (it) *	1985-04-05	1991-07-17	Fidia Farmaceutici	Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
US5166331A (en) *	1983-10-10	1992-11-24	Fidia, S.P.A.	Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
US4478818A (en)	1982-12-27	1984-10-23	Alza Corporation	Ocular preparation housing steroid in two different therapeutic forms
US4521210A (en) *	1982-12-27	1985-06-04	Wong Vernon G	Eye implant for relieving glaucoma, and device and method for use therewith
US4727064A (en) *	1984-04-25	1988-02-23	The United States Of America As Represented By The Department Of Health And Human Services	Pharmaceutical preparations containing cyclodextrin derivatives
US4693885A (en)	1984-07-18	1987-09-15	Nippon Petrochemicals Co., Ltd.	Tetrapyrrole therapeutic agents
US4675338A (en) *	1984-07-18	1987-06-23	Nippon Petrochemicals Co., Ltd.	Tetrapyrrole therapeutic agents
US5128326A (en)	1984-12-06	1992-07-07	Biomatrix, Inc.	Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
FR2577509B1 (fr)	1985-02-21	1987-05-07	Nirvana Espar Systems Sa	Mat de bateau a voile
US4656186A (en) *	1985-04-30	1987-04-07	Nippon Petrochemicals Co., Ltd.	Tetrapyrrole therapeutic agents
US6407079B1 (en) *	1985-07-03	2002-06-18	Janssen Pharmaceutica N.V.	Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US4668506A (en) *	1985-08-16	1987-05-26	Bausch & Lomb Incorporated	Sustained-release formulation containing and amino acid polymer
US4713446A (en) *	1985-09-06	1987-12-15	Minnesota Mining And Manufacturing Company	Viscoelastic collagen solution for ophthalmic use and method of preparation
EP0224987B1 (fr) *	1985-11-29	1992-04-15	Biomatrix, Inc.	Systèmes à base de l'hyaluronanne, de ses dérivés et de ses sels pour la libération de médicaments et leur procédé de fabrication
FR2594438B1 (fr) *	1986-02-14	1990-01-26	Labaz Sanofi Nv	Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant
EP0244178A3 (fr) *	1986-04-28	1989-02-08	Iolab, Inc	Compositions intraoculaires et leur procédé d'utilisation
US4959217A (en)	1986-05-22	1990-09-25	Syntex (U.S.A.) Inc.	Delayed/sustained release of macromolecules
IL80298A (en) *	1986-10-14	1993-01-31	Res & Dev Co Ltd	Eye drops
US4863457A (en)	1986-11-24	1989-09-05	Lee David A	Drug delivery device
US5089509A (en) *	1988-09-15	1992-02-18	Allergan, Inc.	Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US4981871A (en) *	1987-05-15	1991-01-01	Abelson Mark B	Treatment of ocular hypertension with class I calcium channel blocking agents
DE3802158A1 (de) *	1987-08-11	1989-02-23	Hoechst Ag	Vorrichtung zur applikation von implantaten
NZ226171A (en)	1987-09-18	1990-06-26	Ethicon Inc	Gel formulation containing polypeptide growth factor
DE3734223A1 (de)	1987-10-09	1989-04-20	Boehringer Ingelheim Kg	Implantierbares, biologisch abbaubares wirkstofffreigabesystem
US4997652A (en) *	1987-12-22	1991-03-05	Visionex	Biodegradable ocular implants
US4853224A (en) *	1987-12-22	1989-08-01	Visionex	Biodegradable ocular implants
US4920104A (en) *	1988-05-16	1990-04-24	Medchem Products, Inc.	Sodium hyaluronate composition
US4865846A (en)	1988-06-03	1989-09-12	Kaufman Herbert E	Drug delivery system
US5190966A (en) *	1988-07-06	1993-03-02	Health Research, Inc.	Purified hematoporphyrin dimers and trimers useful in photodynamic therapy
US4968715A (en)	1988-07-06	1990-11-06	Health Research, Inc.	Use of purified hematoporphyrin trimers in photodynamic therapy
US5002962A (en)	1988-07-20	1991-03-26	Health Research, Inc.	Photosensitizing agents
US5198460A (en) *	1988-07-20	1993-03-30	Health Research Inc.	Pyropheophorbides and their use in photodynamic therapy
US5093349A (en) *	1988-07-20	1992-03-03	Health Research Inc.	Photosensitizing agents
EP1348437A3 (fr)	1988-09-06	2003-11-19	Pharmacia Aktiebolag	Dérivés de prostaglandine pour le traitement du glaucome ou de l'hypertension oculaire
US5702716A (en)	1988-10-03	1997-12-30	Atrix Laboratories, Inc.	Polymeric compositions useful as controlled release implants
US5457183A (en)	1989-03-06	1995-10-10	Board Of Regents, The University Of Texas System	Hydroxylated texaphyrins
US4935498A (en) *	1989-03-06	1990-06-19	Board Of Regents, The University Of Texas System	Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US5098443A (en) *	1989-03-23	1992-03-24	University Of Miami	Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents
US5171741A (en)	1989-04-21	1992-12-15	Health Research, Inc.	Bacteriochlorophyll-a derivatives useful in photodynamic therapy
US5173504A (en)	1989-04-21	1992-12-22	Health Research, Inc.	Bacteriochlorophyll-a derivatives useful in photodynamic therapy
US5019400A (en) *	1989-05-01	1991-05-28	Enzytech, Inc.	Very low temperature casting of controlled release microspheres
US6271216B1 (en) *	1989-07-24	2001-08-07	Allergan	Stable solution of hyaluronate in a balanced salt medium
US5324519A (en) *	1989-07-24	1994-06-28	Atrix Laboratories, Inc.	Biodegradable polymer composition
US5487897A (en) *	1989-07-24	1996-01-30	Atrix Laboratories, Inc.	Biodegradable implant precursor
US5077049A (en)	1989-07-24	1991-12-31	Vipont Pharmaceutical, Inc.	Biodegradable system for regenerating the periodontium
US5034413A (en) *	1989-07-27	1991-07-23	Allergan, Inc.	Intraocular pressure reducing 9,11-diacyl prostaglandins
US5268178A (en)	1989-09-25	1993-12-07	The Board Of Regents, The University Of Texas System	Biodegradable antibiotic implants and methods of their use in treating and preventing infections
US5503721A (en) *	1991-07-18	1996-04-02	Hri Research, Inc.	Method for photoactivation
US5164188A (en) *	1989-11-22	1992-11-17	Visionex, Inc.	Biodegradable ocular implants
US5025621A (en) *	1990-03-16	1991-06-25	Demarco Vito A	Combination garden implement
US5075115A (en)	1990-04-02	1991-12-24	Fmc Corporation	Process for polymerizing poly(lactic acid)
US5232844A (en)	1990-05-15	1993-08-03	New York Blood Center	Photodynamic inactivation of viruses in cell-containing compositions
US5209926A (en) *	1990-06-12	1993-05-11	Insite Vision Incorporated	Aminosteroids for ophthalmic use
US5124154A (en) *	1990-06-12	1992-06-23	Insite Vision Incorporated	Aminosteroids for ophthalmic use
US5256408A (en) *	1990-06-12	1993-10-26	Insite Vision Incorporated	Aminosteroids for ophthalmic use
US5100431A (en) *	1990-09-27	1992-03-31	Allergan, Inc.	Single stitch suture needle and method
US5492936A (en) *	1990-11-30	1996-02-20	Allergan, Inc.	Bimodal molecular weight hyaluronate formulations and methods for using same
KR0185215B1 (ko) *	1990-11-30	1999-05-01	요시다 쇼오지	서방성 안구삽입용 약제
US5552160A (en)	1991-01-25	1996-09-03	Nanosystems L.L.C.	Surface modified NSAID nanoparticles
US5378475A (en) *	1991-02-21	1995-01-03	University Of Kentucky Research Foundation	Sustained release drug delivery devices
JP3351525B2 (ja) *	1991-06-21	2002-11-25	ジェネティックス・インスティテュート・インコーポレイテッド	骨形成性蛋白医薬処方物
US5356629A (en)	1991-07-12	1994-10-18	United States Surgical Corporation	Composition for effecting bone repair
US5169638A (en)	1991-10-23	1992-12-08	E. R. Squibb & Sons, Inc.	Buoyant controlled release powder formulation
US5543154A (en) *	1991-12-27	1996-08-06	Merck & Co., Inc.	Controlled release nifedipine delivery device
US5656297A (en)	1992-03-12	1997-08-12	Alkermes Controlled Therapeutics, Incorporated	Modulated release from biocompatible polymers
IT1263116B (it)	1992-04-09	1996-07-30	Rotta Research Lab	Derivati basici dell'acido glutammico ed acido aspartico, procedimento per la loro preparazione e loro uso farmaceutico
US5655832A (en)	1992-04-16	1997-08-12	Tir Technologies, Inc.	Multiple wavelength light processor
US5244914A (en)	1992-04-27	1993-09-14	American Cyanamid Company	Stable porfimer sodium compositions and methods for their manufacture
US5178635A (en) *	1992-05-04	1993-01-12	Allergan, Inc.	Method for determining amount of medication in an implantable device
US6217869B1 (en) *	1992-06-09	2001-04-17	Neorx Corporation	Pretargeting methods and compounds
US5472954A (en)	1992-07-14	1995-12-05	Cyclops H.F.	Cyclodextrin complexation
US5324718A (en) *	1992-07-14	1994-06-28	Thorsteinn Loftsson	Cyclodextrin/drug complexation
US5688819A (en)	1992-09-21	1997-11-18	Allergan	Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5972991A (en) *	1992-09-21	1999-10-26	Allergan	Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5922773A (en) *	1992-12-04	1999-07-13	The Children's Medical Center Corp.	Glaucoma treatment
US5494901A (en) *	1993-01-05	1996-02-27	Javitt; Jonathan C.	Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent
US5707643A (en) *	1993-02-26	1998-01-13	Santen Pharmaceutical Co., Ltd.	Biodegradable scleral plug
US5770589A (en) *	1993-07-27	1998-06-23	The University Of Sydney	Treatment of macular degeneration
US5504074A (en) *	1993-08-06	1996-04-02	Children's Medical Center Corporation	Estrogenic compounds as anti-angiogenic agents
US5385887A (en) *	1993-09-10	1995-01-31	Genetics Institute, Inc.	Formulations for delivery of osteogenic proteins
US5540930A (en) *	1993-10-25	1996-07-30	Pharmos Corporation	Suspension of loteprednol etabonate for ear, eye, or nose treatment
US5443505A (en) *	1993-11-15	1995-08-22	Oculex Pharmaceuticals, Inc.	Biocompatible ocular implants
US6051576A (en) *	1994-01-28	2000-04-18	University Of Kentucky Research Foundation	Means to achieve sustained release of synergistic drugs by conjugation
DE4403326C1 (de)	1994-02-03	1995-06-22	Hans Reinhard Prof Dr Koch	Intraokulare Linsenanordnung zur Astigmatismuskorrektur
US5422116A (en) *	1994-02-18	1995-06-06	Ciba-Geigy Corporation	Liquid ophthalmic sustained release delivery system
US5516522A (en) *	1994-03-14	1996-05-14	Board Of Supervisors Of Louisiana State University	Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
US5798349A (en)	1994-03-14	1998-08-25	The General Hospital Corporation	Use of green porphyrins to treat neovasculature in the eye
AU1999995A (en) *	1994-04-08	1995-11-10	Atrix Laboratories, Inc.	An adjunctive polymer system for use with medical device
ES2258495T3 (es) *	1994-04-08	2006-09-01	Qlt Usa, Inc.	Composiciones de administracion liquida de farmacos.
US5466233A (en)	1994-04-25	1995-11-14	Escalon Ophthalmics, Inc.	Tack for intraocular drug delivery and method for inserting and removing same
US6290991B1 (en) *	1994-12-02	2001-09-18	Quandrant Holdings Cambridge Limited	Solid dose delivery vehicle and methods of making same
US6270492B1 (en)	1994-09-09	2001-08-07	Cardiofocus, Inc.	Phototherapeutic apparatus with diffusive tip assembly
US5576311A (en) *	1994-11-30	1996-11-19	Pharmos Corporation	Cyclodextrins as suspending agents for pharmaceutical suspensions
US5811453A (en) *	1994-12-23	1998-09-22	Alcon Laboratories, Inc.	Viscoelastic compositions and methods of use
US5565188A (en)	1995-02-24	1996-10-15	Nanosystems L.L.C.	Polyalkylene block copolymers as surface modifiers for nanoparticles
US6369116B1 (en) *	1995-06-02	2002-04-09	Oculex Pharmaceuticals, Inc.	Composition and method for treating glaucoma
US5869079A (en) *	1995-06-02	1999-02-09	Oculex Pharmaceuticals, Inc.	Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5906920A (en) *	1995-08-29	1999-05-25	The Salk Institute For Biological Studies	Methods for the detection of ligands for retinoid X receptors
US5958954A (en)	1995-09-01	1999-09-28	Allergan Sales, Inc.	Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5776699A (en) *	1995-09-01	1998-07-07	Allergan, Inc.	Method of identifying negative hormone and/or antagonist activities
US5877207A (en) *	1996-03-11	1999-03-02	Allergan Sales, Inc.	Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
IT1288290B1 (it)	1996-06-21	1998-09-11	Fidia Spa In Amministrazione S	Acido ialuronico autoreticolato e relative composizioni farmaceutiche per il trattamento delle artropatie
WO1998010758A1 (fr) *	1996-09-13	1998-03-19	The Regents Of The University Of California	Procede de traitement des maladies retiniennes
US5913884A (en) *	1996-09-19	1999-06-22	The General Hospital Corporation	Inhibition of fibrosis by photodynamic therapy
US6270749B1 (en)	1996-12-11	2001-08-07	Pharmacyclics, Inc.	Use of Texaphyrin in ocular diagnosis and therapy
JP3748970B2 (ja) *	1997-01-31	2006-02-22	電気化学工業株式会社	ヒアルロン酸ナトリウム含有水溶液
US6274614B1 (en)	1997-02-11	2001-08-14	Qlt Inc.	Methods, compositions and articles for reducing or preventing the effects of inflammation
SE9700827D0 (sv)	1997-03-07	1997-03-07	Pharmacia & Upjohn Ab	Ophthalmic composition
US5919970A (en) *	1997-04-24	1999-07-06	Allergan Sales, Inc.	Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
JP2002511868A (ja) *	1997-06-30	2002-04-16	アラーガン・セイルズ・インコーポレイテッド	増殖性硝子体網膜症を治療するためのカルシウム遮断薬
US5994309A (en)	1997-07-25	1999-11-30	Angstrom Pharmaceuticals, Inc.	Anti-invasive and anti-angiogenic compositions and methods
DE69827138T2 (de) *	1997-08-11	2006-02-23	Allergan, Inc., Irvine	Steriles Retinoid enthaltendes biodegradierbares Implantat mit verbesserter Biokompatibilität und Verfahren zu dessen Herstellung
US6306426B1 (en)	1997-08-11	2001-10-23	Allergan Sales, Inc.	Implant device with a retinoid for improved biocompatibility
TW577758B (en) *	1997-10-27	2004-03-01	Ssp Co Ltd	Intra-articular preparation for the treatment of arthropathy
EP0938896A1 (fr)	1998-01-15	1999-09-01	Novartis AG	Compositions pharmaceutiques autoclavables contenant des agents de chelation
US6271220B1 (en)	1998-03-11	2001-08-07	Allergan Sales, Inc.	Anti-angiogenic agents
US6095512A (en) *	1998-03-25	2000-08-01	Vijuk Equipment, Inc.	Accumulator station with stack height control
CA2326456C (fr) *	1998-03-30	2008-12-23	Rtp Pharma Inc.	Composition et procede de preparation de microparticules de substances insolubles dans l'eau
DE69940738D1 (de)	1998-07-09	2009-05-28	Curelight Medical Ltd	Vorrichtung und verfahren zur wirkungsvollen hochenergetischen photodynamischen therapie von akne vulgaris und seborrhoe
CN1311684A (zh)	1998-07-10	2001-09-05	悉尼大学	黄斑变性中新生血管形成的预防治疗
US6261583B1 (en) *	1998-07-28	2001-07-17	Atrix Laboratories, Inc.	Moldable solid delivery system
US20020198174A1 (en)	2001-05-07	2002-12-26	Allergan Sales, Inc.	Disinfecting and solubilizing steroid compositions
US20040152664A1 (en)	1998-09-02	2004-08-05	Allergan, Inc.	Prednisolone compositions
JP2002523475A (ja) *	1998-09-02	2002-07-30	アラーガン・セイルズ・インコーポレイテッド	防腐したシクロデキストリン含有組成物
US6143314A (en)	1998-10-28	2000-11-07	Atrix Laboratories, Inc.	Controlled release liquid delivery compositions with low initial drug burst
US6565874B1 (en) *	1998-10-28	2003-05-20	Atrix Laboratories	Polymeric delivery formulations of leuprolide with improved efficacy
EP1130996B1 (fr)	1998-11-20	2005-04-13	The University of Connecticut	Unite de telemesure a potentiostat generique integree implantable pour capteurs electrochimiques
US6217895B1 (en) *	1999-03-22	2001-04-17	Control Delivery Systems	Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6482854B1 (en)	1999-03-25	2002-11-19	Massachusetts Eye And Ear Infirmary	Glaucoma treatment
US6290713B1 (en)	1999-08-24	2001-09-18	Thomas A. Russell	Flexible illuminators for phototherapy
US6317616B1 (en)	1999-09-15	2001-11-13	Neil David Glossop	Method and system to facilitate image guided surgery
US6331313B1 (en)	1999-10-22	2001-12-18	Oculex Pharmaceticals, Inc.	Controlled-release biocompatible ocular drug delivery implant devices and methods
US6461631B1 (en)	1999-11-16	2002-10-08	Atrix Laboratories, Inc.	Biodegradable polymer composition
US6319273B1 (en)	1999-12-16	2001-11-20	Light Sciences Corporation	Illuminating device for treating eye disease
AUPQ496500A0 (en) *	2000-01-06	2000-02-03	University Of Sydney, The	Kit
US6395294B1 (en) *	2000-01-13	2002-05-28	Gholam A. Peyman	Method of visualization of the vitreous during vitrectomy
EP1997513B1 (fr)	2000-02-10	2012-04-11	Massachusetts Eye & Ear Infirmary	Combinaisons et formulations pour l 'utilisation en PDT dans le traitement des troubles occulaires comprenant des néovascularisations choriodales non désirées
US6726918B1 (en)	2000-07-05	2004-04-27	Oculex Pharmaceuticals, Inc.	Methods for treating inflammation-mediated conditions of the eye
PE20020146A1 (es)	2000-07-13	2002-03-31	Upjohn Co	Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
US6357568B1 (en)	2000-09-27	2002-03-19	Shou Mao Chen	Structure for protecting a luggage shell
AU2002248284A1 (en) *	2000-11-01	2002-08-06	Allergan, Inc.	Compositions for treatment of ocular neovascularization
ATE424808T1 (de) *	2000-11-15	2009-03-15	Chandavarkar Mohan A	Pharmazeutische zusammensetzungen mit corticosteroiden und antiinfektiva
AU2002236495B2 (en)	2000-11-29	2006-05-11	Allergan, Inc.	Intraocular implants for preventing transplant rejection in the eye
US6595945B2 (en) *	2001-01-09	2003-07-22	J. David Brown	Glaucoma treatment device and method
US6713081B2 (en) *	2001-03-15	2004-03-30	The United States Of America As Represented By The Department Of Health And Human Services	Ocular therapeutic agent delivery devices and methods for making and using such devices
TWI298257B (en) *	2001-05-31	2008-07-01	Allergan Inc	Hypotensive lipid and timolol compositions and methods of using same
AR034371A1 (es) *	2001-06-08	2004-02-18	Novartis Ag	Composiciones farmaceuticas
US6713268B2 (en) *	2001-06-26	2004-03-30	Allergan, Inc.	Methods of identifying ocular hypotensive compounds having reduced hyperpigmentation
US20030225152A1 (en) *	2001-09-27	2003-12-04	Andrews Steven W.	3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
CA2463687A1 (fr)	2001-10-18	2003-04-24	Decode Genetics Ehf	Complexes de non-inclusion a base de cyclodextrine
HRP20040406A2 (en) *	2001-11-09	2005-02-28	Eyetech Pharmaceuticals	Methods for treating ocular neovascular diseases
US6885744B2 (en)	2001-12-20	2005-04-26	Rockwell Electronic Commerce Technologies, Llc	Method of providing background and video patterns
US6960346B2 (en)	2002-05-09	2005-11-01	University Of Tennessee Research Foundation	Vehicles for delivery of biologically active substances
CN1411814A (zh) *	2002-08-21	2003-04-23	王晓伟	洗眼液
US6899717B2 (en) *	2002-09-18	2005-05-31	Allergan, Inc.	Methods and apparatus for delivery of ocular implants
US20040137059A1 (en) *	2003-01-09	2004-07-15	Thierry Nivaggioli	Biodegradable ocular implant
WO2004069280A1 (fr)	2003-02-06	2004-08-19	Cipla Ltd	Complexes d'inclusion pharmaceutiques contenant un steroide et un agent antibacterien facultatif
MXPA05008561A (es) *	2003-02-20	2005-11-04	Alcon Inc	Uso de esteroides para tratar personas que sufren de trastornos oculares.
MXPA05008913A (es)	2003-02-21	2005-10-05	Sun Pharmaceutical Ind Ltd	Formulacion oftalmica estable que contiene antibiotico y corticoesteroide.
US20050009910A1 (en)	2003-07-10	2005-01-13	Allergan, Inc.	Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug
RU2006113593A (ru) *	2003-09-23	2006-08-27	Алькон, Инк. (Ch)	Препаративные формы триамцинолона ацетонида и анекортава ацетата для инъекций
US20050250737A1 (en)	2003-11-12	2005-11-10	Allergan, Inc.	Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20060141049A1 (en) *	2003-11-12	2006-06-29	Allergan, Inc.	Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20050101582A1 (en)	2003-11-12	2005-05-12	Allergan, Inc.	Compositions and methods for treating a posterior segment of an eye
CN100548271C (zh) *	2004-01-20	2009-10-14	阿勒根公司	用于眼部的局部治疗、并优选包括有曲安奈德及透明质酸的组合物
US20050244471A1 (en)	2004-04-30	2005-11-03	Allergan, Inc.	Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US20050244465A1 (en)	2004-04-30	2005-11-03	Allergan, Inc.	Drug delivery systems and methods for treatment of an eye
US7771742B2 (en)	2004-04-30	2010-08-10	Allergan, Inc.	Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US20050244463A1 (en)	2004-04-30	2005-11-03	Allergan, Inc.	Sustained release intraocular implants and methods for treating ocular vasculopathies
US8425929B2 (en)	2004-04-30	2013-04-23	Allergan, Inc.	Sustained release intraocular implants and methods for preventing retinal dysfunction
US20050244472A1 (en)	2004-04-30	2005-11-03	Allergan, Inc.	Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US20050244458A1 (en)	2004-04-30	2005-11-03	Allergan, Inc.	Sustained release intraocular implants and methods for treating ocular neuropathies
US8119154B2 (en) *	2004-04-30	2012-02-21	Allergan, Inc.	Sustained release intraocular implants and related methods
US7799336B2 (en)	2004-04-30	2010-09-21	Allergan, Inc.	Hypotensive lipid-containing biodegradable intraocular implants and related methods
US20050244466A1 (en)	2004-04-30	2005-11-03	Allergan, Inc.	Photodynamic therapy in conjunction with intraocular implants
US7589057B2 (en) *	2004-04-30	2009-09-15	Allergan, Inc.	Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems
US20050244461A1 (en)	2004-04-30	2005-11-03	Allergan, Inc.	Controlled release drug delivery systems and methods for treatment of an eye
US20050244478A1 (en)	2004-04-30	2005-11-03	Allergan, Inc.	Anti-excititoxic sustained release intraocular implants and related methods
US20050244462A1 (en)	2004-04-30	2005-11-03	Allergan, Inc.	Devices and methods for treating a mammalian eye
CA2573668A1 (fr) *	2004-07-12	2006-02-16	Allergan, Inc.	Compositions ophtalmiques et procedes de traitement de conditions ophtalmiques
US8802128B2 (en)	2006-06-23	2014-08-12	Allergan, Inc.	Steroid-containing sustained release intraocular implants and related methods
US20070298073A1 (en)	2006-06-23	2007-12-27	Allergan, Inc.	Steroid-containing sustained release intraocular implants and related methods

2004
- 2004-10-14 US US10/966,764 patent/US20050101582A1/en not_active Abandoned
- 2004-11-08 PT PT04810635T patent/PT1682185E/pt unknown
- 2004-11-08 SI SI200431449T patent/SI1997497T1/sl unknown
- 2004-11-08 BR BRPI0416506-3A patent/BRPI0416506A/pt not_active IP Right Cessation
- 2004-11-08 PL PL380453A patent/PL213709B1/pl unknown
- 2004-11-08 PL PL04810635T patent/PL1682185T3/pl unknown
- 2004-11-08 DE DE602004019801T patent/DE602004019801D1/de not_active Expired - Lifetime
- 2004-11-08 KR KR1020067009154A patent/KR20060113709A/ko not_active Ceased
- 2004-11-08 DK DK04810635T patent/DK1682185T3/da active
- 2004-11-08 DE DE602004027773T patent/DE602004027773D1/de not_active Expired - Lifetime
- 2004-11-08 PT PT08016371T patent/PT1997497E/pt unknown
- 2004-11-08 JP JP2006539780A patent/JP5437563B2/ja not_active Expired - Fee Related
- 2004-11-08 ES ES04810635T patent/ES2321305T3/es not_active Expired - Lifetime
- 2004-11-08 NZ NZ546699A patent/NZ546699A/en not_active IP Right Cessation
- 2004-11-08 SI SI200431078T patent/SI1682185T1/sl unknown
- 2004-11-08 AU AU2004289300A patent/AU2004289300B2/en not_active Ceased
- 2004-11-08 CA CA002545878A patent/CA2545878C/fr not_active Expired - Fee Related
- 2004-11-08 WO PCT/US2004/037436 patent/WO2005046641A2/fr not_active Ceased
- 2004-11-08 CN CN201610121191.6A patent/CN105748407A/zh active Pending
- 2004-11-08 ES ES08016371T patent/ES2345018T3/es not_active Expired - Lifetime
- 2004-11-08 AT AT04810635T patent/ATE424220T1/de active
- 2004-11-08 AT AT08016371T patent/ATE471159T1/de active
- 2004-11-08 DK DK08016371.0T patent/DK1997497T3/da active
- 2004-11-08 EP EP04810635A patent/EP1682185B1/fr not_active Expired - Lifetime
- 2004-11-08 EP EP08016371A patent/EP1997497B1/fr not_active Expired - Lifetime
- 2004-11-12 TW TW093134818A patent/TWI362264B/zh not_active IP Right Cessation
2008
- 2008-07-11 US US12/172,194 patent/US8569272B2/en not_active Expired - Fee Related
2009
- 2009-05-22 CY CY20091100549T patent/CY1110469T1/el unknown
- 2009-09-29 AU AU2009222473A patent/AU2009222473B2/en not_active Ceased
2010
- 2010-08-27 CY CY20101100788T patent/CY1110758T1/el unknown
2011
- 2011-08-25 JP JP2011183912A patent/JP5592321B2/ja not_active Expired - Fee Related
2013
- 2013-10-28 US US14/064,960 patent/US9265775B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
WO2005046641A2 (fr)	2005-05-26
CA2545878A1 (fr)	2005-05-26
CA2545878C (fr)	2010-01-12
PL213709B1 (pl)	2013-04-30
EP1997497A3 (fr)	2009-05-13
SI1682185T1 (sl)	2009-06-30
EP1997497A2 (fr)	2008-12-03
DK1997497T3 (da)	2010-09-13
AU2004289300B2 (en)	2009-07-16
KR20060113709A (ko)	2006-11-02
US9265775B2 (en)	2016-02-23
PT1682185E (pt)	2009-04-22
NZ546699A (en)	2009-07-31
PT1997497E (pt)	2010-07-27
JP5592321B2 (ja)	2014-09-17
US20140051671A1 (en)	2014-02-20
DE602004019801D1 (de)	2009-04-16
ES2345018T3 (es)	2010-09-13
ATE471159T1 (de)	2010-07-15
AU2004289300A1 (en)	2005-05-26
TW200528114A (en)	2005-09-01
AU2009222473B2 (en)	2012-03-29
AU2009222473A1 (en)	2009-10-15
SI1997497T1 (sl)	2010-08-31
JP5437563B2 (ja)	2014-03-12
WO2005046641A3 (fr)	2005-11-24
US20080269181A1 (en)	2008-10-30
JP2007510744A (ja)	2007-04-26
EP1997497B1 (fr)	2010-06-16
DE602004027773D1 (de)	2010-07-29
US8569272B2 (en)	2013-10-29
PL380453A1 (pl)	2007-02-05
CY1110758T1 (el)	2015-06-10
BRPI0416506A (pt)	2007-01-09
EP1682185B1 (fr)	2009-03-04
PL1682185T3 (pl)	2009-07-31
ATE424220T1 (de)	2009-03-15
CN105748407A (zh)	2016-07-13
TWI362264B (en)	2012-04-21
JP2012021011A (ja)	2012-02-02
EP1682185A2 (fr)	2006-07-26
US20050101582A1 (en)	2005-05-12
ES2321305T3 (es)	2009-06-04
CY1110469T1 (el)	2015-04-29

Publication	Publication Date	Title
DK1997497T3 (da)	2010-09-13	Sammensætninger og fremgangsmåder til behandling af et posteriort segment af et øje
MXPA05010958A (es)	2006-01-30	Derivados indazol como inhibidores jnk.
HRP20020787B1 (hr)	2012-06-30	Postupak liječenja upotrebom kompleksa ligand-imunogen
EA200300354A1 (ru)	2003-10-30	Хинолиноновые производные в качестве ингибиторов тирозинкиназы
YU69902A (sh)	2005-07-19	Novi derivati piperazina
AR060150A1 (es)	2008-05-28	Heteropentaciclos activos como inhibidores de quinasas, y su uso para tratar trastornos de la proliferacion celular
BR9307700A (pt)	1999-08-31	Formulação para estabilizar uma composição enzimática lìquida, composição enzimática lìquida estabilizada, método para a preparação de uma composição enzimática lìquida estabilizada e método para estabilizar uma composição enzimática lìquida
EA200300323A1 (ru)	2003-08-28	ПРОИЗВОДНЫЕ ГУАНИДИНОБЕНЗАМИДА (ВАРИАНТЫ), КОМПОЗИЦИЯ (ВАРИАНТЫ), СПОСОБ ЛЕЧЕНИЯ ОПОСРЕДОВАННОГО mc4-r ЗАБОЛЕВАНИЯ (ВАРИАНТЫ)
BRPI0416752A (pt)	2007-02-27	composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica
MEP48108A (en)	2011-02-10	4-tetrazolyl-4phenylpiperidine derivatives for treating pain
DE59610077D1 (de)	2003-02-27	Phenyldihydrobenzofurane
BR0306643A (pt)	2004-10-19	Novos compostos de hidroxi alquil/aril ou ceto tiepina como inibidores do transporte co-dependente de ácido biliar-sódio apical
MXPA05009816A (es)	2005-12-05	Composiciones y metodos para el tratamiento de la eyaculacion precoz.
MEP10808A (en)	2010-06-10	Solid drug for oral use
EA200201223A1 (ru)	2003-06-26	Тиенодибензоазуленовые соединения в качестве ингибиторов фактора некроза опухоли
YU57401A (sh)	2004-05-12	Inhibitori aminotransferaza zavisnih od amino kiselina sa razgranatim lancem i njihova upotreba u lečenju diabetske retinopatije
DK1401416T3 (da)	2007-01-08	Anvendelse af C-kit-inhibitorer til behandling af inflammatorisk tarmsygdom
ATE516027T1 (de)	2011-07-15	Orazamid orotat zur vorbeugung von leberschäden
JPS56154416A (en)	1981-11-30	Antipyretic analgesic composition
KR840005147A (ko)	1984-11-03	신규 티에노-피리디논 유도체의 제조방법
DE50300410D1 (de)	2005-05-04	In Wasser redispergierbare Polymerpulver-Zusammensetzungen mit abbindebeschleunigender Wirkung
WO2019232474A3 (fr)	2020-01-16	Compositions et procédés pour augmenter la consommation d'eau par des animaux de compagnie
KR20070059188A (ko)	2007-06-11	잔탄 검 및 아미노산을 함유하는 안과용 조성물
JP2006306757A (ja)	2006-11-09	角膜疾患治療剤
RU2003123198A (ru)	2005-01-27	Способ лечения глазных проявлений заболеваний, передающихся половым путем